Ma-Spore ALL 2020 Study

Korábbi kezelés

• Any previous cytotoxic therapy (chemotherapy/radiotherapy/immunotherapy). Patient pre-treated with short term steroid (< 7 days of duration within last 1 month prior to ALL treatment start) may be enrolled after discussion and written approval from PI. These patients should be treated on at least intermediate arm.
• Doubtful compliance or ability to complete study therapy due to financial, social, familial or geographic reason, or in the judgement of site investigator

Más betegség

• Down syndrome with ALL
• History of previous malignancies or this ALL is a second malignancy
• Any serious uncontrolled medical condition or impending end organ dysfunction that would impair the ability of the subject to receive protocol therapy

Laborértékek

• Persistent renal dysfunction with creatinine more than upper limit of normal for age before start of induction therapy. Patients requiring temporary dialysis without persistent renal dysfunction can qualify.
• Liver dysfunction with direct bilirubin > 10x upper normal limit for age.

Egyéb

• T-lineage ALL
• Mixed phenotype acute leukemia (MPAL) or undifferentiated leukemia
• Mature B-cell leukemia/lymphoma

• Has been diagnosed with B-lineage ALL as evidenced by:
  • BMA blasts > 20% AND
  • Leukemic process in the bone marrow, peripheral blood or any extra medullary tissue with confirmation of B-lymphoid differentiation by flow immunophenotyping or histopathologically
• Age < 41 years of age at enrolment
• Written informed consent obtained from patient or legally acceptable representative (LAR)